Plus Therapeutics, Inc.

NasdaqCM PSTV

Plus Therapeutics, Inc. EPS (Diluted) for the Trailing 12 Months (TTM) ending September 30, 2024: USD -2.23

Plus Therapeutics, Inc. EPS (Diluted) is USD -2.23 for the Trailing 12 Months (TTM) ending September 30, 2024, a 64.15% change year over year. EPS (Diluted) reflects the company's earnings per share adjusted for the potential dilution that could occur if all convertible securities were converted to common stock, providing a more conservative profitability measure.

Plus Therapeutics, Inc. EPS (Diluted) for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -6.22, a 54.10% change year over year.
Plus Therapeutics, Inc. EPS (Diluted) for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -13.55, a 40.78% change year over year.
Plus Therapeutics, Inc. EPS (Diluted) for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -22.88, a -69.73% change year over year.
Plus Therapeutics, Inc. EPS (Diluted) for the Trailing 12 Months (TTM) ending September 30, 2020 was USD -13.48, a 97.54% change year over year.

Key data

Date	EPS (Diluted)	Shares (Diluted, Weighted)	Shares (Basic, Weighted)	Revenue

NasdaqCM: PSTV

Plus Therapeutics, Inc.

CEO	Dr. Marc H. Hedrick M.B.A., M.D.
IPO Date	July 11, 2001
Location	United States
Headquarters	4200 Marathon Boulevard
Employees	20
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.

Key trends

Past 5 years